Bolt Biotherapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing was submitted on June 11, 2026. Bolt Biotherapeutics, Inc. is an emerging growth company incorporated in Delaware, with its principal executive offices in Redwood City, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
The Annual Meeting addressed three proposals. A total of 1,921,567 shares were entitled to vote, with 877,358 shares represented.
- Director Elections (Class II): Two nominees were elected to serve until the 2029 Annual Meeting.
- William P. Quinn: 349,358 votes For, 52,117 votes Withheld, 475,883 Broker Non-Votes.
- Jakob Dupont, M.D.: 377,163 votes For, 24,312 votes Withheld, 475,883 Broker Non-Votes.
- Ratification of Auditors: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- Votes For: 768,336
- Votes Against: 107,471
- Votes Abstaining: 1,551
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote.
Key Facts for Investor Verification
- Verify the full text of the definitive proxy statement (Schedule 14A) filed on April 28, 2026, for details on the director nominees and auditor selection rationale.
- Confirm the total share count and voting participation rate (approx. 45.7% of entitled shares represented).
- Note the significant number of broker non-votes (475,883) regarding the director elections, which may impact future proxy solicitation strategies.
- Review the upcoming 2026 Annual Report (10-K) for the financial metrics absent in this 8-K filing.